STRATA Skin Sciences Inc (SSKN)
Health Services • Health Care
July 28, 2026 STRATA Skin Sciences Appoints Erica Jordan as New CEO STRATA Skin Sciences appoints Erica Jordan as CEO, focusing on expanding patient access to innovative dermatologic therapies. With her extensive experience, Jordan aims to build on the company's success and improve market presence.
May 18, 2026 STRATA Skin Sciences Inc. Reports Groundbreaking Results in Pediatric Vitiligo Treatment STRATA Skin Sciences announced major breakthroughs in treating pediatric vitiligo through a multicenter study showcasing the efficacy of 308-nm excimer laser combined with JAK inhibitors. The results reveal significantly higher repigmentation rates and a commitment to innovative therapy for children with vitiligo.
March 26, 2026 STRATA Skin Sciences Inc. Releases 2025 Annual Report: A Year of Challenges and Innovations STRATA Skin Sciences' 2025 Annual Report reveals a decline in overall revenue but highlights growth in recurring dermatological procedures. The company is focusing on innovative products and expanding its market reach despite facing financial challenges and operational hurdles.
February 19, 2026 STRATA Skin Sciences Confirms Nasdaq Delisting: A Strategic Shift Toward Operational Focus STRATA Skin Sciences, Inc. has announced its decision to delist from Nasdaq, initiating a 'going dark' strategy to reduce regulatory burdens and enhance operational focus. CEO Dr. Dolev Rafaeli assures stakeholders of the company's strong financial position and its commitment to future growth in the dermatological market.
February 18, 2026 STRATA Skin Sciences Expands Dermatological Treatment Options with Johns Hopkins Collaboration STRATA Skin Sciences collaborates with Johns Hopkins Dermatology to introduce the XTRAC® excimer laser, enhancing treatment for inflammatory skin diseases. This partnership aims to expand access to advanced phototherapy and improve patient outcomes.
February 17, 2026 STRATA Skin Sciences Shares Positive Meta-Analysis Results for 308 nm Excimer Laser in Treating Plaque Psoriasis STRATA Skin Sciences has announced promising results from a meta-analysis confirming the effectiveness of the 308 nm Excimer laser in treating plaque psoriasis. The study showed significant reductions in severity scores among patients, highlighting the advantages of MED-guided dosing. This innovation positions STRATA as a leader in dermatological treatment advancements.
December 09, 2025 STRATA Skin Sciences Inc. Reports Strong Momentum at TeraCILAD 2025 STRATA Skin Sciences highlighted its innovative products at TeraCILAD 2025, reporting significant early adoption of TheraclearX® in Mexico. The company aims to enhance patient care and expand its market presence through advanced dermatological solutions.
November 14, 2025 STRATA Skin Sciences Inc. Reports Q3 2025 Financial Results STRATA Skin Sciences reported a slight revenue increase in Q3 2025 but faced challenges in its equipment segment, leading to a net loss. The company continues to invest in marketing and expand its product offerings to enhance market presence.
November 13, 2025 STRATA Skin Sciences Inc. Reports Third Quarter 2025 Financial Results and Corporate Update STRATA Skin Sciences reported a 21% decline in Q3 2025 revenue, highlighting key developments like CPT code expansions and regulatory milestones. The company shows promise with improving gross margins and ongoing legal strategies.
November 06, 2025 STRATA Skin Sciences Secures CMS Recognition for Expanded CPT Codes STRATA Skin Sciences has received CMS confirmation for continued reimbursement under CPT codes for excimer laser treatments, with a 3.5% payment increase for 2026. An upcoming expansion in 2027 will broaden treatment eligibility for various autoimmune conditions, enhancing STRATA's market strategy.
November 05, 2025 STRATA Skin Sciences Set to Release Third Quarter Financial Results on November 13, 2025 STRATA Skin Sciences will report its Q3 2025 financial results on November 13, followed by a conference call for investors. The company focuses on innovative dermatologic treatments, and the upcoming results will provide insights into its performance and strategic direction.
October 28, 2025 STRATA Skin Sciences Secures COFEPRIS Clearance for TheraClearX® in Mexico STRATA Skin Sciences has received COFEPRIS clearance for its TheraClearX® acne treatment system, allowing it to enter the Mexican market. This milestone, achieved in partnership with MINO Labs, positions STRATA to tap into a growing demand for advanced dermatologic solutions in Latin America.
October 20, 2025 STRATA Skin Sciences Reinforces Market Leadership Following Key Litigation Milestones Against LaserOptek STRATA Skin Sciences has achieved significant legal victories against LaserOptek, resulting in expanded market share and a strengthened partner network. The company is poised for growth with the reaffirmation of CPT codes for excimer lasers, which could enhance treatment options for clinics and patients alike.
October 14, 2025 STRATA Skin Sciences Inc. Reports Breakthrough in Treatment of Rare Cutaneous Lymphoma STRATA Skin Sciences has reported a breakthrough in treating poikilodermatous mycosis fungoides, a rare skin lymphoma, using excimer laser therapy. A recent study showed significant improvement in a patient after treatment, highlighting the laser's potential as a targeted option. The company is also working to expand reimbursement for this innovative treatment.
October 03, 2025 STRATA Skin Sciences Inc. Highlights XTRAC® Excimer Laser as a Breakthrough Therapy for Eczema STRATA Skin Sciences highlights the XTRAC® Excimer Laser as a leading therapy for eczema during Eczema Awareness Month. With recent AMA approval for expanded indications, this treatment is backed by robust clinical evidence, offering hope to millions suffering from atopic dermatitis.
September 30, 2025 STRATA Skin Sciences Validates Personalized Medicine with New Study on XTRAC® Excimer Laser Treatment STRATA Skin Sciences has published a pivotal study confirming the efficacy of XTRAC Excimer Laser combined with tacrolimus for plaque-type psoriasis. The research demonstrates significant PASI score reductions, reinforcing the importance of personalized medicine in dermatologic care.
September 22, 2025 STRATA Skin Sciences Inc. Announces Promising Results from Combination Therapy for Vitiligo STRATA Skin Sciences has announced promising results from a study on a combination therapy for vitiligo using its Excimer laser and JAK inhibitors. The trial showed superior efficacy, with a 14.20% improvement in repigmentation and a 100% efficacy rate after 52 weeks, while maintaining an excellent safety profile.
August 14, 2025 STRATA Skin Sciences Inc. Reports Q2 2025 Financial Results: A Mixed Bag Amidst Ongoing Challenges STRATA Skin Sciences' Q2 2025 report shows a revenue decline to $7.66 million amid challenges from the COVID-19 pandemic and geopolitical tensions. Despite these issues, growth in the TheraClear system offers some optimism for future performance.
May 15, 2025 STRATA Skin Sciences Inc. Reports 2025 Q1 Results: Navigating Challenges and Seizing Opportunities STRATA Skin Sciences Inc. reported mixed financial results for Q1 2025, showing revenue growth but ongoing challenges from COVID-19 and supply chain issues. The company is focused on enhancing marketing and product visibility to navigate these hurdles while aiming for financial improvement.
March 28, 2025 STRATA Skin Sciences Inc. Reports 2024 Annual Results: Navigating Challenges and Opportunities STRATA Skin Sciences Inc. reports mixed financial results for 2024, reflecting resilience amid challenges like the COVID-19 pandemic and geopolitical issues. Despite a net loss, the company is focusing on innovation and strategic partnerships to enhance its market position in dermatology.
March 27, 2025 STRATA Skin Sciences Reports Solid Financial Performance for Fourth Quarter and Full Year 2024 STRATA Skin Sciences reported a solid financial performance for Q4 and the full year 2024, achieving a 10% revenue growth driven by equipment sales. The company emphasized operational efficiency and strategic partnerships to enhance its market position.
March 21, 2025 STRATA Skin Sciences to Announce Fourth Quarter and Year-End Results for 2024 STRATA Skin Sciences will announce its fourth quarter and year-end 2024 financial results on March 27, 2025, followed by a conference call at 4:30 p.m. ET. Investors can join via phone or webcast to hear management insights and participate in a Q&A session.
March 20, 2025 STRATA Skin Sciences Unveils Groundbreaking Clinical Study from Japan STRATA Skin Sciences has unveiled promising findings from a clinical study in Japan, showcasing the advantages of its Excimer Laser technology over traditional UVB treatments. Key benefits include deeper follicle penetration, reduced side effects, and faster treatment times, leading to improved patient outcomes in dermatology.
January 23, 2025 SWOT Analysis of STRATA Skin Sciences Inc. in 2025 This article provides a detailed SWOT analysis of STRATA Skin Sciences Inc., focusing on its strengths in patented technologies and market presence, while also addressing its financial weaknesses and competitive threats. It highlights potential growth opportunities in the evolving dermatology landscape and emphasizes the need for strategic navigation of challenges.
November 14, 2024 STRATA Skin Sciences Inc. Reports Q3 2024 Financial Results: Navigating Challenges and Opportunities STRATA Skin Sciences Inc. reported its Q3 2024 financial results, revealing a net income loss of $2.12 million. Despite challenges from geopolitical tensions and the pandemic, the company saw growth in recurring dermatology procedures, positioning itself for future opportunities.
August 14, 2024 STRATA Skin Sciences Inc. Reports Mixed Results in Q2 2024 Financials STRATA Skin Sciences Inc. reported mixed Q2 2024 results, with revenue increasing to $8.041 million but a growing net loss of $1.444 million. The company aims to leverage strong product offerings and strategic initiatives for future growth despite liquidity challenges.
May 15, 2024 STRATA Skin Sciences Inc. Reports Q1 2024 Financial Results: Mixed Signals Amid Significant Developments STRATA Skin Sciences' Q1 2024 results reveal a revenue drop to $6.75 million and increased net losses of $5.71 million. However, strategic initiatives like a reverse stock split and an equity distribution agreement indicate the company's proactive approach to recovery and growth in the dermatology sector.
March 28, 2024 STRATA Skin Sciences Inc. Reports 2023 Annual Results: A Year of Challenges and Strategic Moves STRATA Skin Sciences Inc. faced a challenging 2023 with a 12.1% decline in revenues, leading to increased losses. Strategic debt refinancing and a reverse stock split are among the measures taken to stabilize the company's financial health.